Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 5-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past five years. As of today (2026-09-10), Canopy Growth's 5-Year Sortino Ratio is -0.73.
Canopy Growth (NAS:CGC) 5-Year Sortino Ratio Explanation
The 5-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past five year. It is calculated as the annualized result of the average five-year monthly excess returns divided by the standard deviation of negative returns in the five-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.
Canopy Growth 5-Year Sortino Ratio Related Terms
CGC vs ZTS: 5-Year Sortino Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's 5-Year Sortino Ratio, along with its competitors' market caps and 5-Year Sortino Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canopy Growth 5-Year Sortino Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's 5-Year Sortino Ratio distribution charts can be found below:
* The bar in red indicates where Canopy Growth's 5-Year Sortino Ratio falls into.
The 5-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last five year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 5-Year Sortino Ratio can be calculated by dividing the difference between the five-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past five year.
A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.
Canopy Growth (CGC) has a 5-Year Sortino Ratio of -0.73 as of Sep. 10, 2026. 5-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past five years. View historical data for Canopy Growth and its competitors.
Is Canopy Growth's 5-Year Sortino Ratio too high?
Canopy Growth's current 5-Year Sortino Ratio is -0.73. Overall, Canopy Growth has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canopy Growth's 5-Year Sortino Ratio compare to ZTS?
Canopy Growth's 5-Year Sortino Ratio of -0.73 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Sortino Ratio for a Drug Manufacturers company?
A good 5-Year Sortino Ratio depends on the Drug Manufacturers industry context. However, 5-Year Sortino Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Sortino Ratio mean?
A high 5-Year Sortino Ratio can signal that a stock is expensive relative to its fundamentals. 5-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past five years. View historical data for Canopy Growth and its competitors. Canopy Growth's current 5-Year Sortino Ratio is -0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canopy Growth stock overvalued right now?
Based on GuruFocus' analysis, Canopy Growth (CGC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.71, compared to a current price of $0.93 — trading 31% above its estimated fair value. The current 5-Year Sortino Ratio is -0.73. Canopy Growth's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Sortino Ratio calculated?
5-Year Sortino Ratio is calculated from a company's financial statements. For Canopy Growth (CGC), the current 5-Year Sortino Ratio is -0.73 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canopy Growth (CGC) Overvalued in 2026?
Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued.
The current stock price of $0.93 is trading 31% above its estimated GF Value™ of $0.71.
GuruFocus considers Canopy Growth to be Significantly Overvalued.
Key valuation signals for CGC:
5-Year Sortino Ratio: -0.73
GF Value™: $0.71 vs. price of $0.93 (31% above fair value)
No single metric tells the full story. See the CGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
40GF Score
Get the complete analysis for CGC
5-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGC has been successfully added to your 
